NASDAQ: PRTC - PureTech Health plc

Rentabilité sur six mois: -14.52%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions PureTech Health plc

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise PureTech Health plc

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.

plus de détails
It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2020-11-16
ISIN US7462371060
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.puretechhealth.com
Цена ао 16.75
Changement de prix par jour: -0.4407% (17.7)
Changement de prix par semaine: +5.47% (16.7088)
Changement de prix par mois: -6.71% (18.89)
Changement de prix sur 3 mois: -9.68% (19.51)
Changement de prix sur six mois: -14.52% (20.615)
Changement de prix par an: -38.17% (28.5)
Evolution du prix sur 3 ans: -38.77% (28.78)
Evolution des prix depuis le début de l'année: -9.68% (19.51)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 211.58 1
P/BV 1.24 9
P/E 0 0
EV/EBITDA -3.8 0
Total: 3.63

Efficacité

Nom Signification Grade
ROA, % -9.47 0
ROE, % -14.16 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0.0657

Devoir

Nom Signification Grade
Debt/EBITDA -0.1806 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -61.72 0
Rentabilité Ebitda, % -87.75 0
Rentabilité EPS, % -101.65 0
Total: 0
Plus de détails

Établissements Volume Partager, %
Pentwater Capital Management LP 10244 0.04
Tower Research Capital LLC (TRC) 43 0
UBS Group AG 20 0

ETFPartager, %Rentabilité pour l'année, %Dividendes, %
Amplify BlueStar Israel Technology ETF 0.30643 20.42 0.47569
Invesco Global Listed Private Equity ETF 0.29338 29.43 3.4983
Dimensional International Small Cap ETF 0.02653 5.69 3.34747
SPDR S&P International Small Cap ETF 0.0233 8.94 3.10348
Schwab International Small-Cap Equity ETF 0.0133 10.07 3.20638
SPDR Portfolio Europe ETF 0.00347 8.94 3.66537
Dimensional International Core Equity 2 ETF 0.00136 6.52 3.69996
Avantis International Equity ETF 0.00099 6.46 3.80856
Dimensional International Core Equity Market ETF 0.00032 13.09 3.48343
Vanguard FTSE All-World ex-US Small-Cap ETF 0 9.39 3.09932
Vanguard ESG International Stock ETF 0 6.39 3.07501
0.0611.393.13



Superviseur Titre d'emploi Paiement Année de naissance
Ms. Daphne Zohar Founder, Senior Advisor & Board Observer 3.99M 1971 (54 année)
Dr. Bharatt M. Chowrira J.D., Ph.D. CEO & Executive Director 2.19M 1965 (60 années)
Dr. David R. Elmaleh Ph.D. Co-Founder & Senior Advisor N/A 1948 (77 années)
Ms. Allison Mead Talbot Head of Communications & Investor Relations N/A
Mr. Spencer Ball Senior Vice President of Human Resources N/A
Dr. Eric Elenko Ph.D. Co-Founder & President N/A 1973 (52 année)
Mr. Eric Green M.B.A. Chief Operating Officer N/A
Mr. Charles Sherwood III, J.D., Ph.D. General Counsel & Company Secretary N/A
Dr. Robert S. Langer Jr., Ph.D., ScD Co-Founder & Non-Executive Director 1949 (76 années)
Mr. Michael Inbar CPA, M.B.A. Senior Vice President of Finance

Adresse: United States, Boston. MA, 6 Tide Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.puretechhealth.com